Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
Abdurrahman Tufan, Clinical Consultant and Instructor at Gazi University, shared a post on LinkedIn:
“I’m very pleased to share our new publication in Seminars in Arthritis and Rheumatism:
‘Biologic biologic and biologic JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases.’
Our findings demonstrate the potential of combination targeted therapy to achieve sustained disease control in selected patients with severe and refractory systemic autoinflammatory diseases (SAIDs), including those with persistent inflammation and limited therapeutic options.
In this retrospective longitudinal cohort from the NIH Inflammatory Disease Section, we evaluated advanced combination therapy (ACT) using biologics and or JAK inhibitors in patients with difficult to treat SAIDs.
Among 38 patients, 65 ACT regimens were administered. Following multiple treatment trials:
- 55.3 percent achieved a complete response
- 31.6 percent achieved a partial response
- 68 percent of patients remained on combination therapy at final follow up
- Median duration of ACT was 5 years (range 11 to 186 months)
I am very grateful to all of my co authors and colleagues who contributed to this study, and especially to Daniel L. Kastner, whose mentorship and vision have profoundly influenced our work in autoinflammatory diseases.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?